Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (T2DM). The relationship between hypertension, dyslipidaemia and CVD is now well established. However, the precise link between glycaemia and macrovascular complications has remained unclear. There is now emerging evidence that postprandial glucose (PPG) contributes significantly to CVD risk, although to date there are no large scale interventional studies underway which test the hypothesis that targeting PPG will reduce CVD risk. Until recently, there was no consensus about the definition of postprandial hyperglycaemia. The International Diabetes Federation (IDF) has now developed new clinical guidelines for postprandial glucose and recommend...
OBJECTIVE — With increasing evidence about the cardiovascular risk associated with post-prandial non...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (...
Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
AIMS: The potential importance of postprandial glucose (PPG) control in the development of complicat...
Type 2 diabetes is primarily a disorder of post-prandial glucose regulation, characterized by a grad...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
OBJECTIVE — With increasing evidence about the cardiovascular risk associated with post-prandial non...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (...
Cardiovascular disease (CVD) accounts for almost 75% of mortality in subjects with type 2 diabetes (...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
Type 2 diabetes is characterised by a gradual decline in insulin secretion in response to nutrient l...
AIMS: The potential importance of postprandial glucose (PPG) control in the development of complicat...
Type 2 diabetes is primarily a disorder of post-prandial glucose regulation, characterized by a grad...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
OBJECTIVE — With increasing evidence about the cardiovascular risk associated with post-prandial non...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...
Clinical trials investigating whether glucose lowering treatment reduces the risk of CVD in diabetes...